Regulatory
The latest in regulatory for medical-aesthetics practice owners.
Regulatory
AbbVie Launches Phase 2 Forehead Lines Study
Allergan Aesthetics expands neuromodulator pipeline beyond FDA-approved indications.
Regulatory
Revance Wins FDA Nod for Under-Eye Injectables
The neuromodulator maker gains approval for a new indication, expanding its footprint beyond toxin.
Regulatory
CKD Bio Pursues China Botox Approval—2027 Launch Targeted
South Korean toxin maker seeks regulatory path into world's second-largest aesthetic market.
Regulatory
AEON Releases Expanded Data on ABP-450 Botox Biosimilar
New structural similarity data bolsters ABP-450's case for FDA approval and market entry.
Regulatory
Numeco Wins Panama Approval for Newlux Botulinum Toxin
New toxin entrant expands Latin American footprint with regulatory green light.
Regulatory
BOTOX Masseter Indication Moves Closer to FDA OK
AbbVie's sBLA for jawline prominence shows completed trial data.
Regulatory
Botox Masseter Indication Moves Closer to FDA OK
AbbVie advances toward first-ever neurotoxin approval for jawline contouring.
Regulatory
FDA Accepts BOTOX Cosmetic sBLA for Masseter Prominence
AbbVie's BOTOX Cosmetic wins FDA acceptance for masseter muscle prominence—first and only neurotoxin indication if approved.
Regulatory
FDA Accepts BOTOX Masseter sBLA—Jawline Approval Path Clear
AbbVie advances cosmetic indication for jawline contouring as regulatory pathway accelerates.
Regulatory
AbbVie Wins FDA Review for BOTOX Jawline Indication
Supplemental BLA accepted; masseter prominence treatment moves closer to approval.
Regulatory
FDA Accepts sBLA for Botox in Masseter Prominence
AbbVie advances jawline indication; regulatory path clears for new patient population.
Regulatory
AbbVie Wins FDA Review for BOTOX Jawline Indication
Supplemental BLA for masseter prominence moves forward, opening a new revenue stream for practices.
Regulatory
Indiana Tightens Medical Spa Regulations Under Public Law 136
New state law raises licensing and supervision requirements, affecting independent medspa operations and staffing models.
Regulatory
SKINVIVE by JUVÉDERM Gains FDA Approval for Neck Lines—New Indication Expands Filler Market
Allergan's hyaluronic acid microdroplet formulation clears for neck laxity, opening a new anatomical revenue stream for practices.
Regulatory
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs
Patent litigation over syringe technology could affect filler supply and pricing dynamics.
Regulatory
AbbVie Wins EU Approval for Boey, Its Rapid-Onset Botulinum Toxin
Allergan's new neuromodulator formulation clears European regulators, setting stage for potential U.S. launch and competitive pressure on onset time.
Regulatory
AbbVie Wins EU Approval for Boey, Its Short-Acting Botulinum Toxin
Allergan's rapid-onset neuromodulator clears European regulatory hurdle, expanding the toxin portfolio beyond standard-duration products.
Regulatory
Medicare Begins Price Negotiation on Botox and 14 Other Drugs — Regulatory Headwind for Toxin Economics
Federal price negotiation now includes Botox, creating downward pressure on wholesale costs and rebate structures.
Regulatory
Medicare Begins Price Negotiation for Botox and 14 Other Drugs — Reimbursement Pressure Ahead
Federal price negotiation for Botox signals potential downward pressure on reimbursement rates for therapeutic botulinum toxin in medspa and clinical settings.
Regulatory
Medicare Adds Botox to Price-Negotiation List — What Payers Negotiating Toxin Costs Means for Your Reimbursement
CMS includes Botox among 15 drugs eligible for Medicare price negotiation in 2026, signaling payer focus on high-volume, high-cost injectables.
Regulatory
Galderma Provides Update on Relabotulinum BLA — Third Toxin Competitor Advances Toward FDA Approval
Regulatory progress on Galderma's botulinum toxin candidate keeps competitive pressure on Allergan and Revance.
Regulatory
Galderma Updates Relabotulinum BLA Status With FDA — Third Neuromodulator Nears U.S. Approval
Regulatory progress on Galderma's botulinum toxin candidate; competitive pressure on pricing.
Regulatory
Galderma Provides Update on RelabotulinumtoxinA BLA Review — Third Botulinum Toxin Competitor Advances
Galderma's neuromodulator candidate moves through FDA Biologics License Application review.
Regulatory
Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know
The FDA issued a Complete Response Letter for RelabotulinumtoxinA, delaying Galderma's entry into the U.S. neuromodulator market.
Regulatory
Galderma Gets Complete Response Letter on RelabotulinumtoxinA — What Went Wrong
FDA rejects Galderma's Botox rival on first submission; company faces clinical or manufacturing gaps.
Regulatory
Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle
FDA rejects Galderma's new neuromodulator formulation; shares slide on failed market-entry bid.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.